Adjuvant Immunotherapy for Hepatocellular Carcinoma: Precision Selection of the Optimal Beneficiary Population as the Core Strategy.
0/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
APA
Su JY, Lin LP, et al. (2026). Adjuvant Immunotherapy for Hepatocellular Carcinoma: Precision Selection of the Optimal Beneficiary Population as the Core Strategy.. Journal of hepatology. https://doi.org/10.1016/j.jhep.2026.02.011
MLA
Su JY, et al.. "Adjuvant Immunotherapy for Hepatocellular Carcinoma: Precision Selection of the Optimal Beneficiary Population as the Core Strategy.." Journal of hepatology, 2026.
PMID
41702500 ↗
같은 제1저자의 인용 많은 논문 (5)
- Erratum: Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
- Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection.
- Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
- Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study.
- Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study.